[go: up one dir, main page]

NO20082559L - Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer - Google Patents

Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer

Info

Publication number
NO20082559L
NO20082559L NO20082559A NO20082559A NO20082559L NO 20082559 L NO20082559 L NO 20082559L NO 20082559 A NO20082559 A NO 20082559A NO 20082559 A NO20082559 A NO 20082559A NO 20082559 L NO20082559 L NO 20082559L
Authority
NO
Norway
Prior art keywords
ptk7
antibodies
methods
monoclonal antibodies
human monoclonal
Prior art date
Application number
NO20082559A
Other languages
English (en)
Inventor
Chin Pan
Jonathan Alexander Terrett
Li-Sheng Lu
Original Assignee
Medarex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082559(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Llc filed Critical Medarex Llc
Publication of NO20082559L publication Critical patent/NO20082559L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer isolerte monoklonale antistoffer, spesielt humane monoklonale antistoffer, som binder spesifikt til PTK7 med høy affinitet. Nukleinsyremolekyler som koder for antistoffene ifølge oppfinnelsen, ekspresjonsvektorer, vertsceller og fremgangsmåter for ekspresjon av antistoffene ifølge oppfinnelsen er også fremskaffet. Immunkonjugater, bispesifikke molekyler og farmasøytiske sammensetninger omfattende antistoffene ifølge oppfinnelsen er også fremskaffet. Foreliggende oppfinnelse tilveiebringer også fremgangsmåter for deteksjon av PTK7, så vel som fremgangsmåter for behandling av ulike sykdommer, omfattende kreft og infeksjonssykdommer, ved anvendelse av anti-PTK7-antistoffer.
NO20082559A 2005-12-08 2008-06-02 Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer NO20082559L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74837305P 2005-12-08 2005-12-08
PCT/US2006/046837 WO2007067730A2 (en) 2005-12-08 2006-12-08 Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Publications (1)

Publication Number Publication Date
NO20082559L true NO20082559L (no) 2008-07-07

Family

ID=38123515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082559A NO20082559L (no) 2005-12-08 2008-06-02 Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer

Country Status (21)

Country Link
US (3) US8222375B2 (no)
EP (1) EP1957539B1 (no)
JP (1) JP5401639B2 (no)
KR (1) KR101373464B1 (no)
CN (1) CN101360761B (no)
AU (1) AU2006321841C1 (no)
BR (1) BRPI0619582A2 (no)
CA (1) CA2632552C (no)
DK (1) DK1957539T3 (no)
EA (1) EA017812B1 (no)
ES (1) ES2406063T3 (no)
IL (1) IL191788A (no)
ME (1) ME02002B (no)
NO (1) NO20082559L (no)
NZ (2) NZ569236A (no)
PL (1) PL1957539T3 (no)
PT (1) PT1957539E (no)
RS (1) RS52804B (no)
SG (1) SG177194A1 (no)
SI (1) SI1957539T1 (no)
WO (1) WO2007067730A2 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170080A1 (en) * 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US7960125B2 (en) * 2007-09-25 2011-06-14 The Board Of Trustees Of The Leland Stanford Junior University Identification of thymically derived CD4 T cells by protein tyrosine kinase 7 expression
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
CN101939028A (zh) * 2007-11-30 2011-01-05 百时美施贵宝公司 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
WO2009116764A2 (ko) * 2008-03-17 2009-09-24 연세대학교 산학협력단 Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
WO2011004028A2 (en) 2009-07-10 2011-01-13 Innate Pharma Tlr3 binding agents
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
ES2650630T3 (es) 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Compuestos de pirrolopirimidina para el tratamiento del cáncer
BR112014019990A8 (pt) 2012-02-13 2017-07-11 Bristol Myers Squibb Co Compostos enediinos, seus conjugados e usos e métodos para esses compostos
CA2873878A1 (en) 2012-05-22 2013-11-28 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
PL2956173T3 (pl) 2013-02-14 2017-09-29 Bristol-Myers Squibb Company Związki tubulizyny, metody wykonania i zastosowanie
US9777013B2 (en) 2013-08-14 2017-10-03 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
US9555030B2 (en) * 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity
AU2015253422B2 (en) 2014-04-30 2020-09-03 Abbvie Stemcentrx Llc Anti-PTK7 antibody-drug conjugates
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
US9526801B2 (en) 2015-01-14 2016-12-27 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
KR20180089433A (ko) 2015-12-21 2018-08-08 브리스톨-마이어스 스큅 컴퍼니 부위-특이적 접합을 위한 변이체 항체
CA3010224A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN109069665A (zh) 2016-05-10 2018-12-21 百时美施贵宝公司 具有增强的稳定性的微管溶素类似物的抗体-药物缀合物
AU2017286432B2 (en) 2016-06-14 2020-09-24 Adimab, Llc Anti-coagulation factor XI antibodies
JP7023933B2 (ja) 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
KR20250072712A (ko) 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 합성 면역 수용체 및 이의 사용 방법
EP4098662A1 (en) 2017-05-25 2022-12-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
JP7458997B2 (ja) 2018-05-29 2024-04-01 ブリストル－マイヤーズ スクイブ カンパニー プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
BR112021008083A2 (pt) * 2018-11-07 2021-08-10 Crispr Therapeutics Ag terapia contra o câncer com célula imunológica anti-ptk7
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
SG11202105565UA (en) 2018-11-30 2021-06-29 Bristol Myers Squibb Co Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses
US12478686B2 (en) 2018-12-12 2025-11-25 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102236127B1 (ko) 2019-08-08 2021-04-07 주식회사 하울바이오 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
AR122014A1 (es) * 2020-05-06 2022-08-03 Crispr Therapeutics Ag Receptor de antígenos quimérico enmascarado específico para la proteína tirosina cinasa de tipo 7 (ptk7) y células inmunitarias que expresan el mismo
US20250340670A1 (en) * 2020-07-16 2025-11-06 UIF, (University Industry Foundation), Yonsei University Antibody specifically binding to ptk7 and use thereof
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
CN114213541B (zh) * 2021-12-20 2022-12-30 南京诺唯赞生物科技股份有限公司 一种全能核酸酶的单克隆抗体及其制备方法
MX2024011518A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el tratamiento de tumores que expresan ptk7.
CA3254996A1 (en) 2022-05-19 2023-11-23 Mythic Therapeutics, Inc. PTK7-BINDING PROTEINS WITH pH-DEPENDENT BINDING AND THEIR USES
GB202209196D0 (en) * 2022-06-22 2022-08-10 Almac Discovery Ltd Bi-specific antigen binding molecules
WO2024037621A1 (en) * 2022-08-19 2024-02-22 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ptk7-binding protein and use thereof
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
CN120019079A (zh) * 2022-10-14 2025-05-16 Jsr株式会社 抗体及其用途
EP4683664A1 (en) * 2023-03-23 2026-01-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Antibodies and uses thereof
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025117639A1 (en) * 2023-11-27 2025-06-05 Profoundbio Us Co. Antibodies and methods for ptk7 detection
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250282776A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Bicyclic TLR7 Agonists and Uses Thereof
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
WO1996037610A2 (en) 1995-05-25 1996-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
WO1997012862A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
CA2290789A1 (en) 1997-05-22 1998-11-26 Dale L. Boger Analogs of duocarmycin and cc-1065
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
AU2002245317A1 (en) 2001-01-24 2002-08-06 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
GB0114033D0 (en) 2001-06-09 2001-08-01 Innovata Biomed Ltd Process
US6897034B2 (en) 2001-06-11 2005-05-24 Medarex, Inc. CD10-activated prodrug compounds
IL159225A0 (en) 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
JP2005502703A (ja) 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
EP1487501B1 (en) * 2001-10-09 2012-12-05 The Johns Hopkins University A phosphatase associated with metastasis
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
JP4606739B2 (ja) * 2002-01-18 2011-01-05 ピエール、ファーブル、メディカマン 新規抗ｉｇｆ−ｉｒ抗体およびその使用
US20040197792A1 (en) * 2002-07-15 2004-10-07 Sugen, Inc. Novel Kinases
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
EP1605044A4 (en) * 2003-03-10 2006-12-06 Japan Science & Tech Agency MARKERS FOR DETECTING MESENCHYMAL STEM CELLS AND METHOD FOR IDENTIFYING MESENCHYMAL STEM CELLS USING THE MARKER
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005063987A1 (en) 2003-12-19 2005-07-14 Aveo Pharmaceuticals, Inc. Gp153: methods and compositions for treating cancer
MXPA06012446A (es) 2004-04-29 2007-01-17 Genzyme Corp Metodos y composiciones para el tratamiento de enfermedades poliquisticas.
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
ES2416136T3 (es) 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
CN101939028A (zh) 2007-11-30 2011-01-05 百时美施贵宝公司 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos

Also Published As

Publication number Publication date
SI1957539T1 (sl) 2013-05-31
EA200801509A1 (ru) 2008-12-30
CN101360761B (zh) 2012-09-12
US20100034826A1 (en) 2010-02-11
AU2006321841A1 (en) 2007-06-14
IL191788A (en) 2014-06-30
ES2406063T3 (es) 2013-06-05
AU2006321841C1 (en) 2013-01-24
EA017812B1 (ru) 2013-03-29
JP5401639B2 (ja) 2014-01-29
US8222375B2 (en) 2012-07-17
RS52804B (sr) 2013-10-31
US20120207764A1 (en) 2012-08-16
HK1121174A1 (en) 2009-04-17
IL191788A0 (en) 2009-02-11
SG177194A1 (en) 2012-01-30
BRPI0619582A2 (pt) 2012-12-11
WO2007067730A3 (en) 2007-11-01
JP2009518039A (ja) 2009-05-07
CA2632552C (en) 2015-02-03
PL1957539T3 (pl) 2013-08-30
ME02002B (me) 2013-10-31
WO2007067730A2 (en) 2007-06-14
US20120219557A1 (en) 2012-08-30
CA2632552A1 (en) 2007-06-14
NZ569236A (en) 2012-06-29
KR20080082660A (ko) 2008-09-11
AU2006321841B2 (en) 2012-08-30
CN101360761A (zh) 2009-02-04
US9505845B2 (en) 2016-11-29
PT1957539E (pt) 2013-06-25
KR101373464B1 (ko) 2014-03-14
EP1957539B1 (en) 2013-04-17
US9102738B2 (en) 2015-08-11
EP1957539A2 (en) 2008-08-20
NZ594466A (en) 2012-08-31
DK1957539T3 (da) 2013-05-06

Similar Documents

Publication Publication Date Title
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
NO20080590L (no) Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
CY1121648T1 (el) ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΠΡΟΣ ΠΡΟΓΡΑΜΜΑΤΙΣΜΕΝΟ ΘΑΝΑΤΟ l(PD-l) ΚΑΙ ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΡΚΙΝΟΥ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ANTI-PD-1 ΑΝΤΙΣΩΜΑΤΑ ΜΟΝΑ Ή ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΑΛΛΕΣ ΑΝΟΣΟΘΕΡΑΠΕΥΤΙΚΕΣ
SG170080A1 (en) Human monoclonal antibodies to o8e
NO20064866L (no) IRTA-5 antistoffer og deres anvendelse
NO20080362L (no) CD19-antistoffer og deres anvendelser
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
WO2005042029A3 (en) Psma formulations and uses thereof
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2006116192A3 (en) Irta-1 antibodies and their uses
CY1116843T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα προς συνδετη 1 προγραμματισμενου θανατου (pd-l1)
CY1114151T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα ως προς την κιναση τυροσινης πρωτεϊνης 7 (ρτκ7) και η χρηση αυτων

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDAREX LLC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: E.R. SQUIBB & SONS, US

FC2A Withdrawal, rejection or dismissal of laid open patent application